Elsevier, a world-leading provider of scientific, technical and medical information, is pleased to announce the launch of an open access, online-only journal: New Negatives in Plant Science.
The journal will publish research focusing on negative, unexpected or controversial results in fundamental plant sciences. Published work will include research articles and short communications, as well as commentaries on previously published articles.
The journal is specifically interested in covering areas of molecular-cellular biology, biochemistry, and -omics fields in algae and higher plants. The Editors of New Negatives in Plant Science, Dr Thomas W. Okita of Washington State University and Dr José A Olivares of Los Alamos National Laboratory, hope that the journal will help encourage and drive scientific debate in basic plant sciences by sharing otherwise unpublished studies.
The Editors explain, "In published literature, more often than not we do not refer to the negative, null, or unvarying measurements that do not support a current hypothesis or accepted theory. We do this because of our cultural predispositions for positive reinforcement. Yet, this information can be valuable to the scientific community in a number of ways, for example by helping others to avoid repeating the same experiments as well as encouraging new hypothesis building."
Emma Granqvist, the Publisher responsible for Elsevier's Plant Sciences portfolio of journals, said, "The journal aims to avoid publication bias, making all study results widely available to the plant science community. We are delighted to be able to help achieve this aim and are convinced New Negatives in Plant Science will be a strong addition to Elsevier's open access publications."
The journal will use the article based publishing model, which allows for immediate publication of the final version of a paper without waiting for other articles to be compiled into a full issue.
For more information or to submit an article, go to: http://www.
About Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as over 100 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 2744